QURE Oct 2024 8.000 call
| Previous close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 8.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.0500 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 112 |
ZacksStrength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
GlobeNewswireuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure’s investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.
Simply Wall St.uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
While it may not be enough for some shareholders, we think it is good to see the uniQure N.V. ( NASDAQ:QURE ) share...
